SPE Capital has acquired a majority stake in Vital, Tunisia's leading nutritional supplements producer, marking their ninth investment and aiming to enhance growth and market presence.
Information on the Target
Founded in 2000, Vital is Tunisia's foremost manufacturer of dietary supplements and herbal medicines. With a robust portfolio featuring over 400 high-quality branded products, Vital produces around 8 million units annually, which are marketed both domestically and internationally. The company has established its leadership in the nutritional supplements sector, supported by consistent organic growth and ongoing product innovation. With a workforce of approximately 400 employees, including a substantial number of managerial staff, Vital has solidified its place as the industry's front-runner in Tunisia.
Industry Overview in Tunisia
The nutritional supplements industry in Tunisia has experienced significant growth over the past several years, driven by increasing health awareness among consumers and a rising demand for natural products. This trend is reflected in the expanding market for organic and herbal supplements, which has become a key segment of the broader healthcare and wellness sector. The government's commitment to enhancing healthcare services further supports industry expansion, with policies aimed at fostering innovation in health-related products.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Tunisia's regulatory environment has also evolved, creating opportunities for local and international companies to invest in the health sector. Underscored by an improving trade balance and growing foreign direct investment, the m
Similar Deals
Growth Lending → A & R Care Limited
2025
New Mountain Capital → Smarter Technologies
2025
InvAscent → Apex Hospitals Private Limited
2025
InvAscent → Geri Care Health Services
2025
AltamarCAM Partners → Lanserhof Group
2025
Unifeye Vision Partners → Brooks Eye Associates
2025
SPE Capital
invested in
Vital
in 2023
in a Growth Equity & Expansion Capital deal